Avapritinib

{
  "id": "MLC-T-ONC-000856",
  "term": "Avapritinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with advanced systemic mastocytosis or certain types of gastrointestinal stromal tumors. It is also being studied in the treatment of other types of cancer. Avapritinib blocks certain proteins, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Ayvakit.",
    "An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation."
  ],
  "synonyms": [
    "Ayvakit",
    "PDGFR alpha/KIT mutant-specific inhibitor BLU-285",
    "(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/avapritinib/"
}